Abstract
Background
Injecting drug users are at high-risk of bloodborne virus infections including hepatitis C (HCV), hepatitis B (HBV) and HIV.
Aims
To document screening for and immunisation against bloodborne viruses and to determine the known prevalence and incidence of these infections.
Methods
A cross-sectional survey of clients attending 21 specialist addiction treatment clinics in one health board area in greater Dublin. Data collected on demographic characteristics, serology for HCV, HBV and HIV and immunisation against HBV.
Results
A total of 316 (88%) had been tested for anti-HCV antibody, 244 (68%) had been tested for anti hepatitis B core antibody (anti-HBc), 299 (84%) had been tested for hepatitis B surface antigen (HBsAg) and 307 (86%) had been tested for anti-HIV antibody.The prevalence of anti-HCV, anti-HBc, HBsAg, and anti-HIV were: 66%, 17%, 2% and 11% respectively. The incidence of HCV, HBV and HIV infections were: 24.5, 9.0 and 3.4 per hundred person years respectively. Eighty-one per cent of those in whom it was indicated, had started a targeted HBV immunisation programme in the clinics.
Conclusion
The proportion of clients screened for HCV, HBV and HIV infection has increased since the introduction of a screening protocol in 1998. Targeted vaccination for opiate users against hepatitis B is more successful than previously shown in Ireland. The prevalence and incidence of bloodborne viruses remains high among opiate users attending addiction treatment services, despite an increase in availability of harm reduction interventions.
This is a preview of subscription content, access via your institution.
References
Bolumar F, Hernandez-Aguado I., Ferrer L et al. Prevalence of antibodies to Hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990–2.Int J Epidemiol 1996: 25: 204–209.
Levine O, Vlahov D, Nelson K. Epidemiology of hepatitis B viral infections among drug users: seroprevalence, risk factors and viral interactions.Epidemiol Rev 1999: 16: 418–436.
Madden P, Lamagni T, Hope V. The HIV epidemic in injecting drug users.Commun Dis Rep 1997: 7: 128–130.
Brettle R. HIV and harm reduction for injecting drug users.AIDS 1991: 5: 125–136.
Government Strategy to prevent drug misuse. Dublin: Department of Health (Ireland), 1991.
Smyth R, Keenan E, O’Connor J. Bloodborne viral infection in Irish injecting drug users.Addiction 1998: 93: 1649–1656.
Fitzgerald M, Barry J, O’Sullivan P, Thornton L. Bloodborne virus infections in Dublin’s opiate users.Ir J Med Sci 2001; 170:32–34.
Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry J. Prevalence of antibodies to hepatitis B, hepatitis C and HIV among Irish prisoners: results of a national crosssectional survey,BMJ 2001; 321: 78–82.
Smyth B, Keenan E, O’Connor J. Evaluation of the impact of Dublin’s expanded harm reduction programmes on the prevalence of hepatitis C among injecting drug users with short injectinghistories. J Epidemiol Community Health 1999: 53: 434–435.
Smyth B, O’Connor J, Barry J, Keenan E. Retrospective cohort study examining incidence of HIV and hepatitis C among injecting drug users in Dublin.J Epidemiol Community Health 2003: 57: 310–311.
Introduction of hepatitis B vaccine into childhood immunization services: Management guidelines including information for health workers and parents Geneva, World Health Organization (Department of vaccines and biologicals), 2001.
Immunisation guidelines for Ireland: National Immunisation Committee, Royal College of Physicians of Ireland, 2002.
Mezzelani P, Venturini L, Turrina G, Lugoboni F, Des Jarlais D. High compliance with a hepatitis B virus vaccination programme among intravenous drug users.J Infect Dis 1991, 163(923).
Lamagni T, Davison K, Hope V et al. Poor hepatitis B vaccine coverage in injecting drug users: England 1995 and 1996.Commun Dis Public Health 1999: 2: 174–177.
Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users.Addiction 1997; 92(8): 999–1005.
Van Beek I, Dwyer R, Dore G, Luo K, Kaldor J. Infection with HIV and hepatitis C virus infection among injecting drug users in a prevention setting: retrospective cohort study.BMJ 1998: 317: 433–437.
Smyth B, Barry J, Keenan E. Syringe borrowing persists despite harm reduction interventions.Addiction 2001: 96: 717–727.
Census 96: Principal demographic results. Dublin: Stationery Offic, 1997.
Comiskey C. Estimating the prevalence of opiate drug use in Dublin, Ireland during 1996. Report submitted to the Department of Health.Department of Health. Dublin, 1998.
National Drug Treatment Reporting System (Statistical Bulletin: National Data 1997 and 1998). Dublin, Drug Misuse Research Division (The Health Research Board), 2000.
Garfein R, Doherty M, Monterosso E, Thomas D, Nelson K, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1998; 18(Suppiement 1): 11–19.
Stark K, Bienzle U, Vonk R. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among injecting drug users in Berlin.Int J Epidemiol 1997; 26: 1359–1366.
Grando-Lemaire V, Goisset P, Sorge F et al. [Hepatitis C virus screening in drug users in an addiction out-patient unit].Gastroenterol Clin Biol 2002; 26(12):1091–6.
Peat M, Budd J, Burns S, Robertson R. Audit of bloodborne virus infections in injecting drug users in general practice.Commun Dis Public Health 2000; 3(4): 244–246.
Smyth B, McMahon J, O’Connor J, Ryan J. Knowledge regarding hepatitis C among injecting drug users.Drugs Education Prevention and Policy 1999:6:256–264.
Cook P, McVeigh J, Syed O, Mutton K, Bellis M. Predictors of hepatitis B and C infection in injecting drug users both in and out of treatment.Addiction 2001:96:1787–1797.
Clarke S, Keenan E, Bergin C, Lyons F, Hopkins S, Mulcahy F. The changing epidemiology of HIV infection in injecting drug users in Dublin, Ireland,HIV Med 2001: 2: 236–240.
Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence.Scand J Infect Dis 1996; 28(1): 27–9.
Baker A, Kochan N, Dixon J, Wodak A, Heather N. HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment.Addiction 1995: 90(4): 545–54.
Rumi M, Colombo M, Romeo R et al. Suboptimal response to hepatitis B vaccine in drug users.Arch Intern Med 1991: 151: 574–578.
Quaglio G, Talamini G, Lugoboni F et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response.Addiction 2002: 97: 985–992.
Keating S. Vaccination guidelines for patients attending the ERHA drug treatment clinics. Dublin, Eastern Regional Health Authority, 2000.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grogan, L., Tiernan, M., Geogeghan, N. et al. Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake. Ir J Med Sci 174, 14–20 (2005). https://doi.org/10.1007/BF03169123
Issue Date:
DOI: https://doi.org/10.1007/BF03169123
Keywords
- Drug User
- Human Immunodeficiency Virus Infection
- Harm Reduction
- Inject Drug User
- Opiate User